Jung Beom Son

USPTO Granted Patents = 16 (Patent Applications = 11)

CIPO Patents = 5 (Patent Applications = 5)

EPO Patents = 9 (Patent Applications = 19)

Average Co-Inventor Count = 11.3

ph-index = 2

Forward Citations = 35(Granted Patents)

Location History:

Seoul, KR (2014)
Hwaseong-si, KR (2014 - 2019)
Daegu, KR (2019 - 2021)
Incheon, KR (2022 - 2024)

Company Filing History:

Daegu-gyeongbuk Medical Innovation Foundation

patents

4 out of 146

Hanmi Pharm. Co., Ltd.

patents

4. 3 out of 2,168

Korea Institute of Science and Technology

patents

5. 2 out of 321

Korea Research Institute of Bioscience and Biotechnology

patents

6. 2 out of 63

Hanmi Science Co., Ltd.

patents

7. 1 out of 624

Korea Research Institute of Chemical Technology

patents

8. 1 out of 238

Daegu Gyeongbuk Institute of Science and Technology

patents

9. 1 out of 222

National Cancer Center

patents

10. 1 out of 124

Samsung Life Public Welfare Foundation

Catholic University Industry Academic Cooperation Foundation

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12281121 - N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer (2025-04-21),

2. 12157730 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2024-12-03),

3. 12152021 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2024-11-26),

4. 12037330 - Heteroaryl derivative compounds, and uses thereof (2024-07-16),

5. 11466000 - Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component (2022-10-11),

6. 11447480 - Compound exhibiting enteropeptidase inhibitory activity (2022-09-20),

7. 11208412 - Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease (2021-12-28),

8. 11117892 - Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases (2021-09-14),

9. 10870647 - Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer (2020-12-22),

10. 10442796 - 2,3,5-substituted thiophene compound as protein kinase inhibitor (2019-10-15),

11. RE47451 - Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases (2019-06-24),

12. 10112954 - Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase (2018-10-30),

13. 9156852 - Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases (2015-10-13),

14. 8999973 - Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases (2015-04-07),

15. 8853213 - Bicyclic compound for modulating G protein-coupled receptors (2014-10-07),

Title: Innovative Contributions of Jung Beom Son in Cancer Treatment

Introduction

Jung Beom Son is a notable inventor based in Daegu, South Korea, recognized for his significant contributions to the field of pharmaceuticals. With a total of 16 patents to his name, he has dedicated his research to developing innovative solutions for cancer treatment. His work has focused on the creation of novel compounds that exhibit high efficacy against various types of cancers.

Latest Patents

Among his latest patents, Jung Beom Son has developed an N-containing heteroaryl derivative along with a pharmaceutical composition for the prevention or treatment of cancer. This invention emphasizes its high inhibitory activity against specific protein kinases and effectively targets medullary thyroid cancer and lung cancer cells, particularly those expressing RET fusion genes. Additionally, he has patented a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative. This compound showcases remarkable inhibitory activity against variant forms of the epidermal growth factor receptor (EGFR), proving to be beneficial in treating lung cancer by suppressing the proliferation of affected cell lines.

Career Highlights

Jung Beom Son has a strong professional background, contributing his expertise to notable organizations. He has worked with Voronoi Inc., a company that focuses on advancing medical technologies, and the Daegu-Gyeongbuk Medical Innovation Foundation, dedicated to fostering healthcare innovations. His role in these organizations has allowed him to translate his inventive ideas into practical solutions for serious health challenges.

Collaborations

Collaboration is key to innovation, and Jung Beom Son has worked alongside esteemed colleagues such as Hwan Geun Choi and Nam Doo Kim. Their joint efforts have enhanced the depth of research and development initiatives, further propelling advancements in cancer therapeutics.

Conclusion

Jung Beom Son stands out as a leading inventor in the realm of pharmaceutical innovations, specifically aimed at combating cancer. His dedication to improving treatment options through groundbreaking research and collaboration has made a significant impact on the medical field. With 16 patents, his work continues to inspire future innovations that hold the potential to save lives.

This text is generated by artificial intelligence and may not be accurate.